Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
While the autoimmune character of T1D (type 1 diabetes) is being challenged, it is currently recognized that inflammation plays a key role in its development. We hypothesized that glucotoxicity could contribute to β-cell mass destruction through participation in islet inflammation. We evaluated the...
Saved in:
Main Authors: | Caroline Daems, Sophie Welsch, Hasnae Boughaleb, Juliette Vanderroost, Annie Robert, Etienne Sokal, Philippe A. Lysy |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-01-01
|
Series: | Journal of Diabetes Research |
Online Access: | http://dx.doi.org/10.1155/2019/2813489 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Economic Spectrofluorometric Bioanalysis of Empagliflozin in Rats’ Plasma
by: Bassam Ayoub, et al.
Published: (2021-01-01) -
Role of nitric oxide synthase on brain GABA transaminase activity and GABA levels
by: Vega Rasgado Lourdes A., et al.
Published: (2018-09-01) -
Insulin resistance and β-cell dysfunction in individuals with normal glucose tolerance but elevated 1-h post-load plasma glucose
by: Qianwen Nie, et al.
Published: (2025-02-01) -
Electroencephalography Biomarkers of α5-GABA Positive Allosteric Modulators in Rodents
by: Frank Mazza, et al.
Published: (2025-03-01) -
Eligibility of Dapagliflozin and Empagliflozin in a Real-World Heart Failure Population
by: Erik Håkansson, et al.
Published: (2021-01-01)